Floatz logo

Buprenorphine

Lower Back Pain

Mundipharma Pte Ltd.Small moleculePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Lower Back Pain cohort.

Asset / SponsorPhaseRating
Naltrexone
Mundipharma Pte Ltd.
Phase 4BB
Oxycodone
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3B
Adezunap
Apurano Pharmaceuticals GmbH
Phase 3B
Tapentadol
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3B
OXYMORPHONE CII
Endo USA Inc., a Keenova Therapeutics Company
Phase 3B

View all 16 →

Same molecule, other indications

Buprenorphine is also rated in:

opiate dependenceDormant
BBB
Indicative ·
76 / 100
View asset →
osteoarthritisDormant
BBB
Indicative ·
75 / 100
View asset →
Low Back PainDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →